# Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

> **NCT05526924** · PHASE1 · RECRUITING · sponsor: **University of Chicago** · enrollment: 30 (estimated)

## Conditions studied

- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma
- Head and Neck Carcinoma
- Head and Neck Cancer Stage IV
- Head and Neck Cancers - Throat

## Interventions

- **RADIATION:** Chemoradiation
- **DRUG:** Pamiparib
- **DRUG:** Hydroxyurea
- **DRUG:** Fluorouracil (5FU)
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05526924
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-07
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05526924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05526924, "Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05526924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*